JOP20150154B1 - Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof - Google Patents

Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof

Info

Publication number
JOP20150154B1
JOP20150154B1 JOP/2015/0154A JOP20150154A JOP20150154B1 JO P20150154 B1 JOP20150154 B1 JO P20150154B1 JO P20150154 A JOP20150154 A JO P20150154A JO P20150154 B1 JOP20150154 B1 JO P20150154B1
Authority
JO
Jordan
Prior art keywords
ezetimibe
rosuvastatin
oral administration
preparation
composite formulation
Prior art date
Application number
JOP/2015/0154A
Other languages
Arabic (ar)
Inventor
Hyun Park Jae
Il Kim Yong
Young Jeong Ha
Soo Kim Kyeong
Jun Lee Seung
Soo Woo Jong
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54938391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20150154(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Application granted granted Critical
Publication of JOP20150154B1 publication Critical patent/JOP20150154B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided is a solid composite formulation for oral administration that includes: an ezetimibe-wet granule portion including ezetimibe that is wet-granulated using a fluid-bed granulator; and a rosuvastatin mixture portion including rosuvastatin or a pharmaceutically acceptable salt thereof.
JOP/2015/0154A 2014-06-25 2015-06-24 Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof JOP20150154B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020140078388A KR101977785B1 (en) 2014-06-25 2014-06-25 Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof

Publications (1)

Publication Number Publication Date
JOP20150154B1 true JOP20150154B1 (en) 2021-08-17

Family

ID=54938391

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0154A JOP20150154B1 (en) 2014-06-25 2015-06-24 Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof

Country Status (10)

Country Link
KR (1) KR101977785B1 (en)
AR (1) AR100977A1 (en)
BR (1) BR112016030111A2 (en)
CL (1) CL2016003283A1 (en)
EC (1) ECSP16096477A (en)
JO (1) JOP20150154B1 (en)
SG (2) SG11201610748RA (en)
TW (1) TWI700100B (en)
UY (1) UY36190A (en)
WO (1) WO2015199356A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2016539A3 (en) 2016-09-05 2018-03-14 Zentiva, K.S. A pharmaceutical composition comprising two different active substances and a method of its preparation
CZ2016538A3 (en) 2016-09-05 2018-03-14 Zentiva, K.S. A pharmaceutical composition comprising two different active ingredients
KR102206535B1 (en) * 2016-11-29 2021-01-22 한미약품 주식회사 Oral composite tablet comprising ezetimibe and rosuvastatin
EP3437636A1 (en) * 2017-08-02 2019-02-06 Adamed sp. z o.o. Pharmaceutical composition comprising ezetimibe
KR102500643B1 (en) * 2019-04-18 2023-02-16 한미약품 주식회사 Pharmaceutical combination preparation comprising ezetimibe and losartan
KR20200137243A (en) 2019-05-29 2020-12-09 콜마파마(주) Process for preparation of pharmaceutical combination containing ezetimibe and rosuvastatin
BR112022001783A2 (en) 2019-07-31 2022-03-22 Tecnimede Soc Tecnico Medicinal Sa Immediate release multi-unit solid oral compositions, their methods and uses.
WO2022045759A1 (en) * 2020-08-25 2022-03-03 주식회사 대웅제약 Pharmaceutical composition in single dosage form for treating or preventing hypertension and hypercholesterolemia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100907144B1 (en) * 2007-09-05 2009-07-09 박재섭 The golf club using moving ball
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
EP2448919A2 (en) * 2009-07-02 2012-05-09 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
WO2011012912A2 (en) * 2009-07-28 2011-02-03 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság New granulating process and thus prepared granulate
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
PT2844233T (en) * 2012-05-01 2020-06-25 Althera Life Sciences Llc Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases

Also Published As

Publication number Publication date
UY36190A (en) 2015-10-30
SG10201811586YA (en) 2019-02-27
AR100977A1 (en) 2016-11-16
BR112016030111A2 (en) 2017-08-22
TW201625223A (en) 2016-07-16
KR101977785B1 (en) 2019-05-14
TWI700100B (en) 2020-08-01
KR20160000762A (en) 2016-01-05
SG11201610748RA (en) 2017-01-27
CL2016003283A1 (en) 2017-07-28
WO2015199356A1 (en) 2015-12-30
ECSP16096477A (en) 2017-01-31

Similar Documents

Publication Publication Date Title
JOP20150154B1 (en) Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof
PH12016501196A1 (en) Composite formulation for oral administration comprising ezetimibe and rosuvastatin
EP3096763A4 (en) Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
MX2017016802A (en) Pharmaceutical formulations.
PH12017502376B1 (en) Oral solid formulation containing irinotecan and method of preparing the same
EP3498264A4 (en) Pharmaceutical preparation for oral administration with controlled dissolution rate, the preparation comprising tamsulosin hydrochloride-containing sustained-release pellets
PH12015500823A1 (en) Modified release formulations for oprozomib
MA39765A (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
MX2018012618A (en) Oral pharmaceutical compositions of mesalazine.
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
IL262204A (en) Granule formulation for oral administration
IL276430A (en) Pharmaceutical compound, salts thereof, formulations thereof, and methods of making and using same
EP3530654A4 (en) Quinolinyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition thereof, and use thereof
TR201722603A2 (en) Tablet formulations comprising metformin and sitagliptin processed with hot-melt extrusion
WO2018119108A8 (en) Solid pharmaceutical formulations of asimadoline
SG11201912827TA (en) 7-substituted pyrrolotriazine compounds or pharmaceutically acceptable salts thereof, and preparation methods and uses thereof
EP3600366A4 (en) Process for the preparation of powdered probiotic formulations for monograstic animals.
TW201613586A (en) Pharmaceutical dosage forms
AU2017900496A0 (en) Compounds for Enhancing the Permeation of Active Pharmaceutical Ingredients through Skin
UA92173U (en) Pharmaceutical composition for veterinary